Overview

A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

Status:
Recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company